FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, increasing shot's achieve
RSV reasons hundreds of hospitalizations and deaths amongst seniors each and every 12 months, consistent with knowledge from the Facilities for Illness Keep watch over and Prevention. However the virus too can
